According to a recent LinkedIn post from C Ray Therapeutics, the company has entered a strategic partnership with SHINE Technologies focused on exclusive distribution of no-carrier-added lutetium-177 (Lu-177) in mainland China. The post indicates that C Ray will source n.c.a. Lu-177 from SHINE’s Cassiopeia facility, described as one of North America’s largest dedicated production sites for this isotope.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that C Ray plans to supply this Lu-177 to Chinese radiopharmaceutical developers, biotech firms, and healthcare institutions. Downstream services, including isotope conjugation, fill-and-finish, and quality control, are expected to be provided through C Ray’s 28,000-square-meter Chengdu facility, suggesting an integrated end-to-end isotope solution.
The post further notes that C Ray currently supports more than 30 radioisotopes across over 70 delivered projects, covering programs from IND-enabling studies to Phase III clinical supply. For investors, this partnership could signal an effort to strengthen C Ray’s position as a contract development and manufacturing organization in radiopharmaceuticals, while leveraging SHINE’s production scale to capture growing demand for Lu-177-based radioligand therapies in China.
The arrangement may enhance C Ray’s revenue visibility over time by expanding its role in clinical and potentially commercial supply chains for targeted radiotherapies. It also suggests increased competitive positioning in the Chinese isotope and radioligand therapy market, where secure access to n.c.a. Lu-177 and integrated downstream capabilities can be a key differentiator for both domestic and international drug developers.